Five cases of sprue-like enteropathy in patients treated by olmesartan

Digestive and Liver Disease

Volumn 46, Issue 5, 2014, Pages 465-469

  Théophile, Hélène ^a,b,c   David, Xavier Richard ^d   Miremont Salamé, Ghada ^a,b,c   Haramburu, Françoise ^a,b,c  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c INSERM U657   (France)

^d Gastroenterology Department Private General Hospital Côte Basque Sud   (France)

Author keywords

Angiotensin II receptor antagonist; Enteropathy; Olmesartan; Villous atrophy

Indexed keywords

CREATININE; NEBIVOLOL; OLMESARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL ARTICLE; COLITIS; COLONOSCOPY; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; ENTEROPATHY; FEMALE; FOLLOW UP; GASTROSCOPY; GLUTEN FREE DIET; HOSPITAL DISCHARGE; HUMAN; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; INTESTINE VILLUS ATROPHY; KIDNEY FAILURE; LYMPHOCYTOSIS; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; SIDE EFFECT; SPRUE LIKE ENTEROPATHY; TREATMENT OUTCOME; ULCER; VERY ELDERLY; WEIGHT REDUCTION; ATROPHY; CASE REPORT; CHEMICALLY INDUCED; DUODENUM; GASTROINTESTINAL ENDOSCOPY; ILEITIS; PATHOLOGY;

AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ATROPHY; COLITIS; DEHYDRATION; DIARRHEA; DUODENUM; ENDOSCOPY, GASTROINTESTINAL; FEMALE; HUMANS; ILEITIS; IMIDAZOLES; MALE; TETRAZOLES; WEIGHT LOSS;

EID: 84898846908     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2013.12.014     Document Type: Article

References (9)

1. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 2004, National Institutes of Health, National Heart, Lung, and Blood Institute, US Department of Health and Human Services, Bethesda, MD, NIH Publication No. 04-5230.
2. Oberhuber G., Granditsch G., Vogelsang H. The histopathology of coeliac disease: time for a standardized report scheme for pathologists. European Journal of Gastroenterology and Hepatology 1999, 11:1185-1194.
3. Rubio-Tapia A., Herman M.L., Ludvigsson J.F., et al. Severe spruelike enteropathy associated with olmesartan. Mayo Clinic Proceedings 2012, 87:732-738.
4. Dreifuss S.E., Tomizawa Y., Farber N.J., Davison J.M., Sohnen A.E. Spruelike enteropathy associated with olmesartan: an unusual case of severe diarrhea. Case Reports in Gastrointestinal Medicine 2013, 2013:618071.
5. Stanich P.P., Yearsley M., Meyer M.M. Olmesartan-associated sprue-like enteropathy. Journal of Clinical Gastroenterology 2013, 47:894-895.
6. Rostom A., Murray J.A., Kagnoff M.F. American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease. Gastroenterology 2006, 131:1981-2002.
7. DeGaetani M., Tennyson C.A., Lebwohl B., et al. Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma. American Journal of Gastroenterology 2013, 108:647-653.
8. FDA Potential Signals of Serious Risks/New Safety Information Identified by the Adverse Event Reporting System (AERS) between April-June 2012. Information posted on line by the FDA on October 18, 2012 2013, Available from: www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm324020.htm [accessed 05.08.13].
9. FDA FDA Drug Safety Communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil 2013, Available from: www.fda.gov/Drugs/DrugSafety/ucm359477.htm [accessed 05.08.13].